94844-37-8

Basic information

• Product Name: (E)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-2-butenoic Acid Ethyl Ester
• Synonyms: (E)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-2-butenoic Acid Ethyl Ester
• CAS NO: 94844-37-8
• Molecular Formula: C₁₂H₂₄O₃Si
• Molecular Weight: 244.40266
• Product Categories: Aliphatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 94844-37-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform, DCM, Ethyl Acetate, Methanol
• CAS DataBase Reference: (E)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-2-butenoic Acid Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-2-butenoic Acid Ethyl Ester(94844-37-8)
• EPA Substance Registry System: (E)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-2-butenoic Acid Ethyl Ester(94844-37-8)

Safety Data

• Hazardous Substances Data: 94844-37-8(Hazardous Substances Data)

Usage

Uses

(E)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-butenoic Acid Ethyl Ester is an protected intermediate in the synthesis of 4-Amino-γ-butyrolactones via asymmetrical synthesis.

Upstream product

• 10080-68-9 (E)-ethyl 4-hydroxybut-2-enoate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 102191-92-4 tert-butyldimethylsiloxyacetaldehyde 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 2459-05-4 (E)-4-ethoxy-4-oxobut-2-enoic acid 
• 623-73-4 diazoacetic acid ethyl ester 

Downstream Products

• 944410-66-6 ethyl (3S,αR)-3-[N-benzyl-N-(α-methylbenzyl)-amino]-4-(tert-butyldimethylsilyloxy)butanoate 
• 173423-74-0 (E)-4-(tert-Butyl-dimethyl-silanyloxy)-but-2-enoic acid 4-fluoro-phenyl ester 
• 1361293-78-8 1-(benzyloxycarbonyl)-6-((tert-butyldimethylsilyloxy)methyl)-4-(4-(2-(2,6-dichlorophenoxy)ethoxy)phenyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 1361293-77-7 1-(benzyloxycarbonyl)-2-((tert-butyldimethylsilyloxy)methyl)-4-(4-(2-(2,6-dichlorophenoxy)ethoxy)phenyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 1361293-70-0 1-benzyloxycarbonyl-6-((tert-butyldimethylsilyloxy)methyl)-4-(4-(2-(2-chlorophenoxy)ethoxy)phenyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid 

Relevant articles and documents

Structure revision of poecillastrin c and the absolute configuration of the β-hydroxyaspartic acid residue

The planar structure of poecillastrin C (1) was revised through selective reduction of the ester carbon. The absolute configuration of the β-hydroxyaspartic acid (OHAsp) residue was determined to be D-threo by Marfey's analysis. The acid hydrolysate of the reduction product of 1 liberated (2R, 3R)-2-amino-3, 4-dihydroxybutanoic acid, demonstrating that the β-carboxyl group in poecillastrin C was esterified. The structures of poecillastrins B-D and 73-deoxychondropsin A were also revised.

Interrogating Pd(II) Anion Metathesis Using a Bifunctional Chemical Probe: A Transmetalation Switch

Ligand metathesis of Pd(II) complexes is mechanistically essential for cross-coupling. We present a study of halide→OH anion metathesis of (Ar)PdII complexes using vinylBPin as a bifunctional chemical probe with Pd(II)-dependent cross-coupling pathways. We identify the variables that profoundly impact this event and allow control to be leveraged. This then allows control of cross-coupling pathways via promotion or inhibition of organoboron transmetalation, leading to either Suzuki-Miyaura or Mizoroki-Heck products. We show how this transmetalation switch can be used to synthetic gain in a cascade cross-coupling/Diels-Alder reaction, delivering borylated or non-borylated carbocycles, including steroid-like scaffolds.

PYRROLOPYRIMIDINE AND PURINE DERIVATIVES

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.